GlassScriptPhysician profile
Alan Joseph Naim
NPI 1588008890
$7,020.25
in general payments reported to CMS, 2019-2025
32 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $102 · 2021: $166 · 2022: $328 · 2023: $617 · 2024: $3,279 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,507 · Consulting Fee: $1,100 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,506.68 |
| Consulting Fee | $1,100.00 |
| Education | $162.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,100.00 | 2024 | |
| Janssen Biotech, INC. | $616.33 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $525.02 | 2023-2025 | |
| Conmed Corporation | $455.61 | 2019-2021 | |
| Madrigal Pharmaceuticals | $414.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $370.50 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.41 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $352.49 | 2024-2025 | Voquezna |
| Abbvie INC. | $342.10 | 2019-2025 | |
| Pfizer INC. | $328.60 | 2019-2025 | |
| Ardelyx, INC. | $290.25 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $286.54 | 2022-2024 | Linzess |
| Celltrion USA INC. | $206.63 | 2024-2025 | Zymfentra, Vegzelma |
| Teleflex LLC | $198.36 | 2025 | Titan Sgs Bailout Chuck |
| Lucid Diagnostics INC. | $161.86 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $140.61 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $120.85 | 2024 | Austedo Xr |
| Lilly USA, LLC | $119.35 | 2024 | Omvoh |
| Celgene Corporation | $114.51 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $91.88 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $82.30 | 2020-2024 | Entyvio |
| Aimmune Therapeutics, INC. | $59.55 | 2024 | |
| Gilead Sciences, INC. | $56.79 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $35.00 | 2024 | Utaswako Afp-L3 |
| Intercept Pharmaceuticals, INC. | $29.65 | 2019 | |
| Braintree Laboratories, INC. | $27.97 | 2023 | Sutab |
| Ipsen Biopharmaceuticals, INC | $25.78 | 2025 | Iqirvo |
| Olympus America INC. | $25.16 | 2023 | Visiglide |
| Exact Sciences Corporation | $24.14 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $21.64 | 2025 | Wegovy |
| Endogastric Solutions, INC | $14.98 | 2023 | Esophyx |
| Redhill Biopharma INC. | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Naim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.